Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]
News [2440]
Articles [146]
Editorials [8]
Conferences [101]
elearning [12]
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to...
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer
Inherited changes in BRCA genes linked to increased risk of multiple myeloma
Inherited changes in BRCA genes linked to increased risk of multiple myeloma
New drug target discovered for aggressive form of prostate cancer
New drug target discovered for aggressive form of prostate cancer
NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
ESMO 2024: Immunotherapy shows promise for men with specific types of prostate cancer
ESMO 2024: Immunotherapy shows promise for men with specific types of prostate cancer
Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer
Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers
ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers
ESMO 2024: Repeat immune checkpoint inhibitor therapy not recommended for advanced kidney cancer
ESMO 2024: Repeat immune checkpoint inhibitor therapy not recommended for advanced kidney cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation